Uterine fibroid-related infertility: mechanisms and management
- PMID: 38453041
- DOI: 10.1016/j.fertnstert.2024.02.049
Uterine fibroid-related infertility: mechanisms and management
Abstract
Fibroids are a common pathology and increasingly observed in women seeking medical treatment for infertility. The longer reproductive horizon because of improvements in medical care and current trend for women to postpone childbearing are making fibroid-related infertility increasingly common. This review aimed to critically analyze the association between uterine fibroids and infertility, mechanisms by which uterine fibroids may impair fertility, and management of myoma-related infertility. The association of fibroids with infertility is a source of controversy. As the focus of this review is infertility, it is crucial to analyze the mechanisms by which fertility may be impaired by the presence of fibroids. Current management strategies involve mainly surgical interventions, including myomectomy by hysteroscopy, laparotomy, or laparoscopy, and nonsurgical approaches, such as uterine artery embolization and focused ultrasound performed under radiologic or echographic guidance. The risks and benefits of each option should be discussed with patients, and several factors need to be considered, including the skills of surgeons and availability of different resources in various centers. Concerning the efficacy of oral gonadotropin-releasing hormone antagonists (i.e., elagolix, relugolix, and linzagolix), they were shown to have a rapid impact on heavy menstrual bleeding (HMB) in >70% of women. When used without add-back therapy, these drugs cause a significant reduction in fibroid volume, namely, approximately 50% from baseline to week 24. Further studies are required to determine the best protocol and optimal dosage if a reduction in myoma volume is the main goal, as in case of myoma-related infertility.
Keywords: Uterine fibroids; infertility; medical therapy; surgery.
Copyright © 2024 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of Interests J.D. is a member of the Scientific Advisory Board of ObsEva, Theramex, and Gedeon Richter, outside the submitted work. H.S.T. reports funding from AbbVie and honoraria from Netscape and was president of the American Society for Reproductive Medicine, outside the submitted work. L.M. has nothing to disclose. M.-M.D. reports honoraria from Theramex and Gedeon Richter, outside the submitted work.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials